6,180 reports of this reaction
4.2% of all DOXORUBICIN reports
#4 most reported adverse reaction
NEUTROPENIA is the #4 most commonly reported adverse reaction for DOXORUBICIN, manufactured by Amneal Pharmaceuticals LLC. There are 6,180 FDA adverse event reports linking DOXORUBICIN to NEUTROPENIA. This represents approximately 4.2% of all 148,755 adverse event reports for this drug.
Patients taking DOXORUBICIN who experience neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEUTROPENIA is moderately reported among DOXORUBICIN users, representing a notable but not dominant share of adverse events.
In addition to neutropenia, the following adverse reactions have been reported for DOXORUBICIN:
The following drugs have also been linked to neutropenia in FDA adverse event reports:
NEUTROPENIA has been reported as an adverse event in 6,180 FDA reports for DOXORUBICIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEUTROPENIA accounts for approximately 4.2% of all adverse event reports for DOXORUBICIN, making it a notable side effect.
If you experience neutropenia while taking DOXORUBICIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.